Brian Schwartz
Technik-/Wissenschafts-/F&E-Leiter bei INTENSITY THERAPEUTICS, INC.
Vermögen: 46 596 $ am 31.05.2024
Profil
Brian D.
Schwartz is currently the Chief Medical Officer & Director at Cyclacel Pharmaceuticals, Inc. and a Director at Enlivex Therapeutics Ltd.
He is also the Executive VP-Clinical Development at Intensity Therapeutics, Inc. Previously, he worked as a Director at Infinity Pharmaceuticals, Inc. from 2021 to 2023 and as a Director at Mereo BioPharma Group Plc from 2020 to 2022.
He also served as an Independent Director at LifeSci Acquisition Corp.
in 2020.
From 2008 to 2020, he held the position of Chief Medical Officer and Head of Research & Development at ArQule, Inc. Additionally, he has experience as the Chief Medical Officer at Alaunos Therapeutics, Inc. Dr. Schwartz obtained his doctorate degree from the University of Pretoria in 1985.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 03.05.2024 | 16 707 ( 1,14% ) | 44 106 $ | 31.05.2024 | |
| 31.03.2024 | 1 828 ( 0,01% ) | 2 486 $ | 31.05.2024 | |
| 30.05.2023 | 30 919 ( 0,03% ) | 3 $ | 31.01.2024 |
Aktive Positionen von Brian Schwartz
| Unternehmen | Position | Beginn |
|---|---|---|
| ENLIVEX THERAPEUTICS LTD. | Direktor/Vorstandsmitglied | 01.12.2020 |
| CYCLACEL PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 25.01.2024 |
| INTENSITY THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ehemalige bekannte Positionen von Brian Schwartz
| Unternehmen | Position | Ende |
|---|---|---|
| INFINITY PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 24.07.2023 |
| MEREO BIOPHARMA GROUP PLC | Direktor/Vorstandsmitglied | 10.11.2022 |
| VINCERX PHARMA, INC. | Direktor/Vorstandsmitglied | 23.12.2020 |
| ARQULE, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.03.2020 |
| ALAUNOS THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Brian Schwartz
| University of Pretoria | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 6 |
|---|---|
| MEREO BIOPHARMA GROUP PLC | Health Technology |
| ENLIVEX THERAPEUTICS LTD. | Health Technology |
| CYCLACEL PHARMACEUTICALS, INC. | Health Technology |
| INFINITY PHARMACEUTICALS, INC. | Health Technology |
| ALAUNOS THERAPEUTICS, INC. | Health Technology |
| INTENSITY THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
ArQule, Inc.
 ArQule, Inc. Pharmaceuticals: MajorHealth Technology ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company was founded in 1993 and is headquartered in Burlington, MA. | Health Technology |
LifeSci Acquisition Corp.
 LifeSci Acquisition Corp. Financial ConglomeratesFinance LifeSci Acquisition Corp. operates as a blank check company. It was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. The company was founded on December 19, 2018 and is headquartered in New York, NY. | Finance |
